Kedokteran & Kesehatan editorial
Open AccessOA2022
Effects of Liraglutide on Gastrointestinal Functions and Weight in Obesity: A Randomized Clinical and Pharmacogenomic Trial
Liraglutide, a GLP-1 receptor agonist, was evaluated over 16 weeks for its effects on weight and gastric functions in obesity, with pharmacogenomic analysis of GLP1R rs6923761 and TCF7L2 rs7903146 polymorphisms.
Daniel B. Maselli; J. Atieh; M. Clark; Deborah J. Eckert; Ann L. Taylor; P. Carlson; Duane D. Burton; I. Busciglio; W. Harmsen; A. Vella; Andres Acosta; Michael Camilleriยท Obesityยท 2022ยท DOI 10.1002/oby.23481
The core problem
Obesity is a chronic disease with limited effective treatments. Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in reducing weight, but its effects on gastrointestinal functions and the influence of genetic variants remain unclear. This study aimed to determine the effects of liraglutide versus placebo over 16 weeks on weight and gastric functions, and to evaluate associations of single-nucleotide polymorphisms (SNPs) in GLP1R (rs6923761) and TCF7L2 (rs7903146) with the effects of liraglutide.
Innovation
This was a randomized, double-blind, placebo-controlled clinical and pharmacogenomic trial. Participants with obesity received subcutaneous liraglutide or placebo for 16 weeks. The primary outcomes were weight change and gastric functions (e.g., gastric emptying, satiety). Genotyping was performed for GLP1R rs6923761 and TCF7L2 rs7903146. The study was conducted by a multidisciplinary team including Daniel B. Maselli, J. Atieh, M. Clark, Deborah J. Eckert, Ann L. Taylor, P. Carlson, Duane D. Burton, I. Busciglio, W. Harmsen, A. Vella, Andres Acosta, and Michael Camilleri, and published in the journal Obesity.
Introduction
Obesity is a chronic disease with limited effective treatments. Liraglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, has shown promise in reducing weight, but its effects on gastrointestinal functions and the influence of genetic variants remain unclear. This study aimed to determine the effects of liraglutide versus placebo over 16 weeks on weight and gastric functions, and to evaluate associations of single-nucleotide polymorphisms (SNPs) in GLP1R (rs6923761) and TCF7L2 (rs7903146) with the effects of liraglutide.
Why it matters
The findings of this trial may provide insights into the mechanisms by which liraglutide affects weight and gastrointestinal functions, and whether genetic variants in GLP1R and TCF7L2 modulate these effects. Such knowledge could inform personalized treatment approaches for obesity. The study's limitations and clinical implications are not discussed in the available abstract.
Who should read this
Pembaca Research Digest dan praktisi rumpun ini.
Opening member contentโฆ